Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.
## Materials

| Antibodies | Yes (indicate where provided): | n/a |
|------------|--------------------------------|-----|
| For commercial reagents, provide supplier name, catalogue number and RRID, if available. | | It was not used in this study. |

| Cell materials | Yes (indicate where provided): | n/a |
|----------------|--------------------------------|-----|
| **Cell lines**: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | It was not used in this study. |
| **Primary cultures**: Provide species, strain, sex of origin, genetic modification status. | | It was not used in this study. |

| Experimental animals | Yes (indicate where provided): | n/a |
|----------------------|--------------------------------|-----|
| **Laboratory animals**: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | It was not used in this study. |
| **Animal observed in or captured from the field**: Provide species, sex and age where possible | | It was not used in this study. |
| **Model organisms**: Provide Accession number in repository (where relevant) OR RRID | | It was not used in this study. |

| Plants and microbes | Yes (indicate where provided): | n/a |
|---------------------|--------------------------------|-----|
| **Plants**: provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | | It was not used in this study. |
| **Microbes**: provide species and strain, unique accession number if available, and source | | It was not used in this study. |

| Human research participants | Yes (indicate where provided): | n/a |
|-----------------------------|--------------------------------|-----|
| Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | Page 3 /line 25-26 Patients and methods/Para1 |
| Provide statement confirming informed consent obtained from study participants. | Page 3 /line 26-27 Patients and methods/Para1 |
| Report on age and sex for all study participants. | Table 1 |
### Design

| Study protocol | Yes (indicate where) | n/a | This study is a retrospective study, and the registration number cannot be provided at present. |
|---------------|----------------------|-----|-----------------------------------------------------------------------------------------------|
| For clinical trials, provide the trial registration number OR cite DOI in manuscript. | | | |

| Laboratory protocol | Yes (indicate where) | n/a | This study does not involve laboratory protocol. |
|---------------------|----------------------|-----|-------------------------------------------------|
| Provide DOI or other citation details if detailed step-by-step protocols are available. | | | |

| Experimental study design (statistics details) | Yes (indicate where) | n/a | |
|-----------------------------------------------|----------------------|-----|-----------------------------------------------------------------------------------------------|
| State whether and how the following have been done, or if they were not carried out. | | | |

| Sample size determination | | | This is a preliminary exploratory study and the sample size was not calculated. |
|---------------------------|-----|---------------------------------|

| Randomisation | | | This is an exploratory study and does not involve randomization. |
|---------------|-----|---------------------------------|

| Blinding | | | No blinding method is involved in this study. |
|----------|-----|---------------------------------|

| Inclusion/exclusion criteria | Page2/Line10-12 Abstract/Para 2; Page3/Line 19-21 Patients and methods/Para1 Exclusion criteria: Page3/Line 21-23 Patients and methods/Para1 | |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|

| Sample definition and in-laboratory replication | Yes (indicate where) | n/a | This is a retrospective clinical study and does not involve replication. |
|--------------------------------------------------|----------------------|-----|-----------------------------------------------------------------------------------------------|
| State number of times the experiment was replicated in laboratory | | | |

| Define whether data describe technical or biological replicates | | | This is a retrospective clinical study and does not involve replication. |
|---------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------|

| Ethics | Yes (indicate where) | n/a | |
|--------|----------------------|-----|-----------------------------------------------------------------------------------------------|
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | Page3 /line 25-26 Patients and methods/Para1 | | |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | | Experimental animals were not included in this study. |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | | | This study does not involve specimen or field samples. |

| Dual Use Research of Concern (DURC) | Yes (indicate where) | n/a | |
|------------------------------------|----------------------|-----|-----------------------------------------------------------------------------------------------|
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | | | This study does not involve dual use research of concern. |
### Analysis

| Attrition | Yes (indicate where) | n/a |
|-----------|----------------------|-----|
| State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance. | Page3/line21-23 Patients and methods/Para1 | |

| Statistics | Yes (indicate where) | n/a |
|------------|----------------------|-----|
| Describe statistical tests used and justify choice of tests. | | This is an exploratory study, which is mainly descriptive and does not involve data statistics. |

| Data Availability | Yes (indicate where) | n/a |
|-------------------|----------------------|-----|
| State whether newly created datasets are available, including protocols for access or restriction on access. | | This is an exploratory study. The datasets are still being supplemented and are not available at this time. |
| If data are publicly available, provide accession number in repository or DOI or URL. | | The data are not publicly available. |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible. | | The data are not publicly available. |

| Code Availability | Yes (indicate where) | n/a |
|-------------------|----------------------|-----|
| For all newly generated code and software essential for replicating the main findings of the study: | | |
| State whether the code or software is available. | | There is no newly generated code or software. |
| If code is publicly available, provide accession number in repository, or DOI or URL. | | There is no newly generated code or software. |

### Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|--------------------------------|-----------------------------------------------|-----|
| MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR. | Section Acknowledgement. | |
| State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript. | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. | |

Article information: http://dx.doi.org/10.21037/tau-20-1055.